Company Performance Metrics
- Daniel Gareau: CEO
- Jason Hawkes: CMO
SurgiVance Inc. is developing a confocal microscopy -based imager that produces rapid, high-resolution, digitally-colored images of biopsied tissue specimens. It is designed to supplant hematoxilin and eosin (H&E) staining – a labor-intensive, almost universal process considered the gold-standard for tissue preparation in advance of examination
by a pathologist under a standard light-field microscope. Revolutionizing the workflow from biopsy to histopathological image will allow physicians to make faster clinical decisions, delivering significant time and cost savings for the clinic and an enhanced patient experience. SurgiVance’s images can integrate into electronic medical records and be instantly shared with other healthcare providers, including remote pathologists, or input into third-party diagnostic AIs. The SurgiVance product is engineered to be smaller, simpler, lower-cost, and more broadly useful than competing products. Our initial target market will be Mohs surgery practices, where skin cancers are excised in multiple stages.